Impact Biomedical (IBO) Cost of Revenue (2025)

Impact Biomedical (IBO) posted Cost of Revenue of $1000.0 for Q3 2025, down 90.91% on a QoQ basis from $11000.0 in Q2 2025.

Impact Biomedical (IBO) Cost of Revenue (2025) Analysis & Trends

Impact Biomedical's Cost of Revenue history runs 1 years deep, the most recent figure standing at $1000.0 for Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	167.22 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	392.80 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	296.00 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	145.00 Mn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Impact Biomedical	47.41 Mn	47.39 Mn	-	-

Download Data